MASH Therapies May Address Liver Fibrosis in ALD, Researchers Say

For decades, the standard medical approach to alcohol-associated liver disease (ALD) has been singular and unyielding: stop drinking, or face the consequences.

While abstinence remains the bedrock of clinical management, a new signal from the latest research suggests that we might finally be closing the gap on the underlying biological damage that persists even when the alcohol stops.

At The Liver Meeting 2026 in Denver this week, researchers presented findings that indicate metabolic dysfunction-associated steatohepatitis (MASH) therapies may offer a viable path to addressing liver fibrosis in patients with ALD. As HCPLive reported, the study—which examined the effects of zalfermin, cagrilintide, and semaglutide—changes how doctors might treat a condition long defined by its social stigma and clinical complexity.

The core challenge in ALD has always been the lack of FDA-approved pharmacological interventions to reverse fibrosis. Vijay Shah, MD, highlighted that progress in this field has lagged for years, largely due to the deep-seated stigma surrounding alcohol use and the sheer biological difficulty of untangling alcohol-related injury from other metabolic factors.

In a field where the “so what” is often measured in transplant lists and mortality, the possibility of an active, targeted treatment is significant.

“Sustained abstinence remains the cornerstone of ALD management, and no approved therapies target the underlying fibrogenic process,” the researchers noted in their presentation.

A critical question for any trial involving alcohol consumption is whether the observed benefits are merely a byproduct of the patients drinking less. Data from the trial showed that while alcohol consumption trended downward across all groups, there was no statistically significant difference between those receiving the investigational therapies and those given a placebo.

This suggests that the liver-healing effects observed may stem from the drugs’ direct biological impact on the organ rather than just a reduction in alcohol intake.

This nuance is particularly relevant given the rise of the MetALD phenotype, where patients present with both alcohol-related injury and metabolic risk factors. Many participants in this study exhibited these overlapping traits, which likely contributed to the therapeutic response. It forces a necessary shift in perspective: we are no longer just treating a behavior; we are treating a complex, multi-factorial disease state.

Of course, this research is still in its early stages, and the medical community remains cautious. Future trials face design challenges, particularly in how to safely and effectively study these drugs in a population that continues to drink. The safety and tolerability profiles of these therapies in such a specific, high-risk group remain a primary focus for clinicians like Dr. Shah.

This affects the healthcare sector and the patients caught in the middle of this clinical gap. If these therapies prove effective, they could eventually sit alongside existing treatments for alcohol use disorder, providing a dual-pronged approach that addresses both the psychological drivers of the disease and the physical scar tissue that can lead to cirrhosis and liver failure.

The approach is shifting from purely behavioral management to a more nuanced, biological one. The question of how to integrate these high-cost, high-tech metabolic therapies into the standard of care for ALD remains unresolved. Until larger, longitudinal trials can confirm these early signals, the medical community will continue to look for ways to bridge the distance between promising biomarkers and actual, long-term patient outcomes.

For those tracking the evolution of clinical guidelines, the 2024 ACG clinical guideline on alcohol-associated liver disease remains the essential baseline for current practice, while the multisociety Delphi consensus statement provides the updated framework for understanding the evolving nomenclature of fatty liver disease.